To include your compound in the COVID-19 Resource Center, submit it here.

ALT-801: Phase Ib/II data

Data from 34 chemotherapy-refractory patients in the dose-escalation and expansion stages of an open-label, U.S. Phase Ib/II trial

Read the full 182 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE